• ScreenPro (SCRN) has completed its acquisition of Concierge Medical Consultants from Datametrex AI (DM)
  • Concierge Medical is an arm’s length private medical concierge services provider
  • The company paid a purchase price of C$1,800,000 in common shares
  • It views the acquisition as a strategic component of its post-pandemic business plan
  • ScreenPro Security is a medical technology company that offers proprietary testing methods and medical alerting software
  • ScreenPro (SCRN) is unchanged trading at $0.02 per share

ScreenPro (SCRN) has completed its acquisition of Concierge Medical Consultants from Datametrex AI (DM).

Concierge Medical is an arm’s length private medical concierge services provider incorporated under the laws of British Columbia. It’s comprised of a small group of board-certified practicing emergency physicians and was founded by Dr. Jibran Sharif, MD, CCFP EM, RDMS.

The company issued 36,000,000 common shares priced at C$0.05 per share for an aggregate purchase price of $1,800,000.

Lena Kozovski, CEO of ScreenPro, stated,

“We are pleased to complete the acquisition of Concierge Medical. Dr. Sharif and I have worked together for the last year on the pandemic and COVID-19 testings, and I look forward to moving Concierge Medical to the next level. Consumers view concierge services as a viable model for future medical care needs and the completion of this acquisition is a pivotal part of our post-pandemic business plan.”

Concierge Medical has become ScreenPro’s wholly-owned operating subsidiary. Sharif and Kozovski now make up Concierge Medical’s Board of Directors, with Sharif remaining as President and assuming the role of ScreenPro’s Chief Medical Officer.

ScreenPro Security is a medical technology company that offers proprietary testing methods and medical alerting software.

ScreenPro (SCRN) is unchanged trading at $0.02 per share as of 9:30 am ET.

More From The Market Online

Theralase advances cancer research following private placement

Theralase Technologies (TSXV:TLT) has closed a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

Canada’s federal budget: What investors need to know

Canada’s federal budget in has sent ripples through the investor community, revealing shifts in fiscal policies and spending priorities.

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.